

# SHARED EXPERIENCE OUTCOMES IN 1,416 WOMEN WITH UNEXPLAINED INFERTILITY TESTED WITH RECEPTIVADX™ (BCL6): EFFECT OF TREATMENT ON SUBSEQUENT EMBRYO TRANSFER

**Authors:** Angress Dan, Cicero Diagnostics Inc

**IVF Center Contributors:** (1) NYU Langone Fertility Center, (2) NYU Langone Fertility Center ACWS, (3) CCRM Fertility Center NY, (4) CCRM Fertility Center SF, (5) Central Coast Fertility San Louis Obispo (6) FCI Fertility Center Buffalo Grove (7) Nashville Fertility Center, TN, (8) Piedmont Fertility (Ashville, NC), (9) Ganin Fertility Center (Cairo, Egypt). (10) Aimee Eyvazzadeh, M.D (San Ramon, CA) (11) AZ Ctr for Fertility Studies (Scottsdale AZ), (12) Northwell Fertility (Manhasset, NY)

## Objective

Provide larger scale outcomes in women tested for BCL6, comparing positive treated to untreated BCL6 negative controls. The study size provides new independent support for the existing published studies.

## Design

A retrospective analysis of over 1400 patients from 12 independent IVF centers tested for BCL6 looking specifically at ongoing pregnancies and livebirth (LBR) as an endpoint on the next transfer after testing.

## Materials and Methods

All patients included presented with UI (unexplained infertility) with clinical information taken from the ReceptivaDx™ test requisition form, including number of failed IFVs, recurrent pregnancy loss, or prior diagnoses of suspected hydrosalpinx, adenomyosis, and PCOS. For positive BCL6 results, only patients treated with surgical laparoscopy or GnRH agonists (depot leuprolide acetate or Zoladex®) were included. To minimize bias, any samples with limited clinical history were not included. Centers provided treatment and outcomes and patients were then deidentified.

## Results:

### BCL6 Patients Treated with GnRH agonist (Lupron) or Laparoscopy vs Untreated Negative

	Patients Tested	Pregnancy Rates	Live Births and On-going pregnancies	Pregnant and Lost	Not Pregnant
<b>BCL6 Positive Treated</b>	688	480 (70%)	404 (59%)	78 (11%)	209 (30%)
<b>BCL6 Negative Untreated</b>	728	498 (68%)	412 (57%)	85 (12%)	231 (32%)

The average failure rate in the study was 1.9 and 88% of the patients were PGS tested.

## Conclusions

We report by far, the largest number of outcomes results for BCL6 tested patients using pregnancy rates and LBR data provided retrospectively by twelve independent centers. The cumulative outcomes support earlier published data on the value of BCL6 testing in women with UI undertaking IVF. In those studies, results showed three key takeaways; Positive BCL6 expression (histologic score, >1.4) was highly associated with endometriosis,<sup>1,2,5</sup> positive BCL6 expression untreated was strongly associated with poor reproductive outcomes compared to negative BCL6 expression (12% vs 52% respectively),<sup>3,4</sup> and follow-up independent studies continue to show the success of treatment on BCL6 positive patients<sup>6,7</sup> With this analysis, we add to the collective studies demonstrating the consistent value of BCL6 in identifying and treating women with UI, IVF

failure, and recurrent pregnancy loss. Limitations of this study include the retrospective design and reliance on self-reported clinical characteristics.

**Financial Support:** The author is an employee of Cicero Diagnostics, the licensee of the ReceptivaDx test.

## References

1. Jung-Yoon Yoo, et al *KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance*, Scientific Reports 2017 Jul 28. On-line
2. Evans-Hoeker, E., et al *Endometrial BCL6 Overexpression in Eutopic Endometrium of Women With Endometriosis*, Reproductive Sciences 2016, May 24
3. Almquist,, Laura D, et al., *Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study*, Fert & Ster, Dec 2017 108 (6) P:1063–1069
4. Likes, C.E., Cooper, L.J., Efird, J. et al. *Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression*, J Assist Reprod Genet (2019) 36: 483
5. Fox, Chelsea W, et al. *Unexplained recurrent pregnancy loss and unexplained infertility: twins in disguise*, Human Reproduction Open, pp. 1–8, 2019
6. Angress D., *Outcomes in women with IVF failure who tested positive for BCL6 using ReceptivaDx™ testing: Effect of treatment on subsequent embryo transfer*, Fert & Ster, April 2020, Vol. 113 Issue 4
7. Summers, Gustin, et al. *Does GnRh down regulation amongst women with abnormal BCL6 and/or Beta 3 Integrin expression improve implantation rates?* F&S September 2020 Vol. 114, No. 3, Supplement